We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pfizer said it will add participants as young as 12 to the global phase 3 trial of its COVID-19 vaccine candidate to glean more information on how the treatment affects different age groups. Read More
Johnson & Johnson (J&J) has agreed to contribute an additional $1 billion to resolve multiple opioid lawsuits over its alleged role in the opioid addiction crisis at the state, city, county and tribal level. Read More
The FDA has approved Regeneron Pharmaceuticals’ Inmazeb (atoltivimab, maftivimab and odesivimab-ebgn), a combination of three monoclonal antibodies, making it the agency’s first approved treatment for the Ebola virus. Read More
President Trump’s touting of Regeneron Pharmaceuticals’ COVID-19 antibody treatment as a cure for the disease that would imminently become available to all Americans for free has come under congressional scrutiny. Read More
Barely more than one in four air cargo companies that will be involved in distributing COVID-19 vaccines are well-prepared to do so, a new survey has found. Read More
Serious quality control violations discovered in the past year at Eli Lilly’s Branchburg, N.J., facility — a site that is preparing to manufacture the company’s COVID-19 antibody — are being “aggressively” addressed and will not impact product quality or safety, the drugmaker said Wednesday. Read More
HHS on Wednesday shot down a story claiming that department officials had asked the FDA to consider COVID-19 Emergency Use Authorizations (EUAs) as “pre-licensures” even as the FDA issued a statement detailing why pre-licensure approvals would not be appropriate for COVID-19 vaccines. Read More